---
schema_version: "secwatch.filing_event.v1"
accession: "0000914121-23-000149"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T08:58:29.782340+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q3 net sales up 9% but guides down; adjusted EPS loss $0.03 vs prior guidance for profit

## Summary
- Q3 net sales $80.7M (+9.1% YoY); GAAP loss per share $0.24 vs $0.13 loss last year; adjusted loss per share $0.03.
- Med Tech sales $22.9M (+16.6%); Auryon +42.8% to $10.4M; AngioVac -15.7% to $5.5M.
- Gross margin 50.2%, down 200 bps YoY; adjusted EBITDA $4.3M vs $6.7M.
- FY2023 guidance cut: net sales now $338-342M (from $342-348M); adjusted EPS now loss $0.06 to loss $0.01 (from profit $0.01-0.06).
- Cash $30.1M; total debt $50M; generated $1.4M operating cash in Q3.

## SEC filing metadata
- accession: 0000914121-23-000149
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000091412123000149/0000914121-23-000149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000091412123000149/an59017198-8ki.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914121-23-000149
- JSON: https://secwatch.observer/filing/0000914121-23-000149.json
- Plain text: https://secwatch.observer/filing/0000914121-23-000149.txt

## Key facts
- Earnings Releases
  ANGIODYNAMICS INC reported the third quarter of fiscal year 2023, which ended February 28, 2023 results: revenue $80.7 million, net income net loss of $9.5 million, or a loss per share of $0.24, EPS loss per share of $0.24. Guidance lowered.
  - Period: the third quarter of fiscal year 2023, which ended February 28, 2023
  - Revenue: $80.7 million
  - Net income: net loss of $9.5 million, or a loss per share of $0.24
  - EPS: loss per share of $0.24
  - Guidance: lowered
  - Result: reported results
  source text: Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance Fiscal Year 2023 Third Quarter Highlights • Net sales of $80.7 million increased 9.1% compared to the prior-year quarter o Med Tech net sales of $22.9 million increased 16.6% o Med Device net sales of $57.8 million increased 6.4% • Gross margin of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000091412123000149/0000914121-23-000149-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.